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Histopathologic characteristics of biopsies 
from dogs undergoing surgery with concurrent 
gross splenic and hepatic masses: 125 cases 
(2012–2016)
Fernando J. Leyva1*, Catherine A. Loughin1, Curtis W. Dewey1,2, Dominic J. Marino1, Meredith Akerman3 
and Martin L. Lesser3
Abstract 
Objective: To investigate the histopathologic characteristics of concurrent splenic and liver masses in dogs undergo-
ing splenectomy and liver mass biopsy/resection. Medical records of 125 client-owned dogs found to have splenic 
mass or masses and a liver mass or masses during surgery were examined. Signalment (age, sex, breed), body weight, 
and results of histopathology were recorded for all dogs.
Results: Twenty-seven percent (34/125) of the dogs in this study had no evidence of malignancy in either the liver or 
the spleen. Sixty of 125 dogs (48.0%) had malignancy in the spleen and liver, and 56 (56/60, 93.3%) of those dogs had 
the same malignancy in both organs. Signalment was similar to that in other reports of splenic pathology. In this clini-
cal population of dogs, 27% of dogs with concurrent gross splenic and liver masses discovered intraoperatively had 
benign lesions in both locations and therefore had a favorable prognosis.
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Introduction
Splenic masses are frequently encountered in dogs. They 
may be diagnosed in dogs that present with non-trau-
matic hemoabdomen or incidentally upon imaging or 
surgery. Lesions in the spleen may be the result of benign 
(i.e. lymphoid hyperplasia, hematoma, cyst, abscess, etc.) 
or malignant (i.e. hemangiosarcoma (HSA), metastatic 
sarcoma/carcinoma, malignant histiocytosis, lymphosar-
coma (LSA), etc.) processes [1–4]. Hemangiosarcoma has 
been reported by some researchers as the most common 
splenic mass in dogs [1, 5]; however, others have reported 
higher prevalence of benign lesions [2–4]. In contrast, the 
prevalence of benign versus malignant lesions has been 
well established in dogs with non-traumatic hemoabdo-
mens. The study by Johnson et al. [5] proposed the “law of 
two-thirds” in dogs with non-traumatic hemoabdomens, 
in which two-thirds of dogs with splenomegaly have neo-
plasia and two-thirds of these had hemangiosarcoma.
Similar to splenic masses, hepatic masses may be 
benign (i.e. nodular hyperplasia (NH), extramedullary 
hematopoiesis, cyst, abscess, hematoma, etc.) or malig-
nant (i.e. hepatocellular carcinoma (HCC), LSA, malig-
nant histiocytosis, HSA, metastatic carcinoma/sarcoma, 
etc.) [6–9]. The presence of a concurrent hepatic mass 
or masses (HM) with a splenic mass or masses (SM) has 
been reported to be associated with a metastatic disease 
process [10, 11]. Hemangiosarcoma and other malignant 
splenic neoplasms have been reported to metastasize to 
the liver, via splenic venous blood, lymphatic drainage, 
or transcoelomic metastasis [12, 13]. However, it has also 
been reported that there is a high prevalence of benign 
hyperplastic hepatic nodules in dogs with increasing age 
[14]. The presence of HM, SM, and the potential for gross 
metastatic disease are important considerations for many 
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clients in determining whether they wish to accept the 
costs, risks, and morbidity associated with surgery given 
the possibility of a poor long-term prognosis [15].
The purpose of this retrospective study was to describe 
the prevalence of benign versus malignant masses in 
dogs with SM and HM undergoing surgery, and to report 
patient signalment (age, sex, breed), weight, and histo-
pathological diagnosis of both organs.
Main text
Methods
Inclusion criteria/case selection
A database search in infinity1 of our medical records 
revealed 369 splenectomies which were performed 
between January 1, 2012, and January 1, 2016. The medi-
cal records of all 369 dogs were reviewed. Only dogs with 
both SM and HM found at surgery were included in this 
study. One hundred twenty-five client-owned dogs were 
identified with confirmed SM and HM at the time of sur-
gery and were included in this study. Data obtained from 
the medical records included histopathological diagnosis 
of both splenic and hepatic tissue, signalment (age, sex, 
breed), and body weight. All surgeries were performed by 
surgeons (ACVS diplomates) or surgical residents under 
supervision of ACVS diplomates, after written consent 
was provided by the owners. Each dog had a splenectomy 
performed in conjunction with a liver biopsy (via liver 
lobectomy or incisional biopsy).
Histopathologic evaluation
Following splenectomy, each whole spleen and liver 
sample were fixed in 10% buffered formalin, and were 
reviewed by board-certified pathologists from a local, 
outside laboratory (Antech Diagnostics2). Sections from 
microscopic examination were selected from various 
regions of the spleen and liver samples submitted; gen-
erally multiple sections were obtained from the mar-
gin of any nodule and adjacent unaffected parenchyma. 
Microscopic evaluation of multiple selected sections 
was accomplished from 4- to 6-μm sections of paraffin-
embedded tissue mounted on glass microslides and 
stained with hematoxylin and eosin. Additional stains 
were performed at the discretion of the pathologist. 
Based on the microscopic features of the tissues, the 
lesions were characterized histologically.
Statistical analysis
Descriptive statistics (mean, SD, median, minimum, 
and maximum values for age and weight; frequency and 
percentage for categorical variables such as sex, breed, 
benign or malignant lesions, type of lesion) were calcu-
lated for the study sample. A cross-tabulation of spleen 
and liver status (benign or malignant) was constructed to 
determine the percent of dogs with benign splenic lesions 
and benign liver lesions, the percent of dogs with benign 
splenic lesions and malignant liver lesions, the percent of 
dogs with malignant splenic lesions and malignant liver 
lesions, and the percent of dogs with malignant splenic 
lesions and benign liver lesions.
Inferential statistics were also conducted for the study 
sample. After testing for equality of variance by Levene’s 
test, a series of independent-samples t tests were con-
ducted for age and weight. A series of Chi squared analy-
ses for patient sex was also conducted. Values of P ≤ 0.05 
were considered significant for all analyses. All analyses 
were performed using SAS version 9.4.3
Results
There were 125 dogs included in this study. Mean age 
was 10.1 years (range 4–15 years). There were one female 
intact, 59 female spayed, 11 male intact, and 54 male 
neutered. Mean weight was 27.8  kg (range 4–58.3  kg). 
There were 42 mixed breed dogs; 24 Golden R etriev-
ers; 7 Labrador Retrievers; 6 German Shepherd Dogs; 4 
Beagles; 3 each Cocker Spaniels, Rottweilers, and York-
shire Terriers; 2 each Australian Shepherd, Cane Corso, 
English Springer Spaniel, and Pekingese; and 1 each of 25 
other breeds. There were no significant differences in age, 
weight, or sex between dogs with malignant lesions ver-
sus those with concurrent benign lesions. The data gen-
erated and analyzed, examining these associations, are 
summarized in Additional file 1.
Of the 125 dogs, 42 (33.6%) had benign SM and 83 
(66.4%) had malignant SM. One of the dogs had two 
malignant SM. The most common malignant splenic 
lesion was HSA (69/84, 82.1%). The most common 
benign splenic lesion was NH (27/62, 43.5%). Sixty-
seven dogs (53.6%) had malignant HM. The most com-
mon malignant hepatic lesion was HSA (51/68, 75%). 
The most common benign hepatic lesion was NH (26/69, 
37.7%). All biopsy results and number of dogs per type 
(benign versus malignant) are summarized in Tables  1 
and 2.
Thirty-four of the dogs (27%) had benign SM and 
HM. Of the 60 dogs with malignant splenic and liver 
lesions, 56 (93.3%) had the same malignancy in both 
organs. Forty-six dogs (76.7%) had HSA in the spleen 
and the liver, 3 (5%) dogs had leiomyosarcoma (LMS) 
in both organs, 3 (5%) dogs had histiocytic sarcoma in 
1 Infinity; Henry Schein ImproMed, Oshkosh, WI 54902, United States.
2 Antech Diagnostics; New Hyde Park, NY 11042, United States. 3 SAS version 9.4; SAS Institute Inc., Cary, NC 27513, United States.
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both organs (one of these dogs additionally had splenic 
HSA), 1 (1.7%) dog had liposarcoma in both organs, 
one dog had anaplastic sarcoma in both organs, one 
dog had undifferentiated sarcoma in both organs, and 
1 dog had LSA in both organs. In the four dogs with 
exclusively different malignancies, one dog had liposar-
coma in the spleen and LSA in the liver, one dog had 
osteosarcoma in the spleen and undifferentiated sar-
coma in the liver, one dog had LMS in the spleen and 
stromal sarcoma in the liver, and the last dog had mast 
cell tumor in the spleen and HSA in the liver. Seven of 
the dogs (5.6%) with benign SM had malignant HM, 23 
of the dogs (18.4%) with malignant SM had benign HM. 
The more salient numbers and percentages of dogs with 
benign and malignant lesions are summarized in Fig. 1.
Discussion
The identification of concurrent SM and HM poses a 
conundrum to clinicians. While the incidence of splenic 
malignancy in SM and non-traumatic hemoabdomens has 
been well-documented [1, 2, 16, 17], only two studies have 
looked at the association of HM in dogs with splenic HSA 
[11, 18]. Our study is the first to report the prevalence of 
benign versus malignant masses in dogs with concurrent 
Table 1 Summarization of histopathology results 
for spleen and liver biopsies
Splenic biopsies obtained 
in the study
No. (% 
of total)
No. (% of 125 
dogs)
Malignant splenic lesions
Hemangiosarcoma 69 (82.1) 69 (55.2)
Leiomyosarcoma 4 (4.8) 4 (3.2)
Histiocytic sarcoma 3 (3.6) 3 (2.4)
Undifferentiated sarcoma 2 (2.4) 2 (1.6)
Anaplastic spindle cell sarcoma 1 (1.2) 1 (0.8)
Stromal sarcoma 1 (1.2) 1 (0.8)
Osteosarcoma 1 (1.2) 1 (0.8)
Mast cell tumor 1 (1.2) 1 (0.8)
Liposarcoma 1 (1.2) 1 (0.8)
Lymphosarcoma 1 (1.2) 1 (0.8)
Total No. malignant splenic lesions (%) 84 (100)a 84 (67.2)a
Benign splenic lesions
Nodular hyperplasia 27 (43.5) 27 (21.6)
Hematoma 11 (17.7) 11 (8.8)
 Infarct 5 (8.1) 5 (4)
Extramedullary hematopoiesis 4 (6.5) 4 (3.2)
Myelolipoma 3 (4.8) 3 (2.4)
Plaques 3 (4.8) 3 (2.4)
Necrosis 2 (3.2) 2 (1.6)
Splenitis 2 (3.2) 2 (1.6)
Congestion 2 (3.2) 2 (1.6)
Lipoma 1 (1.6) 1 (0.8)
Lymphoid hyperplasia 1 (1.6) 1 (0.8)
Hemosiderosis 1 (1.6) 1 (0.8)
Total No. benign splenic lesions (%) 62 (100)a 62 (49.6)a
Liver biopsies obtained in the study No. (% 
of total)
No. (% of 125 
dogs)
Malignant liver lesions
Hemangiosarcoma 51 (75) 51 (40.8)
Hepatocellular carcinoma 4 (5.9) 4 (3.2)
Histiocytic sarcoma 3 (4.4) 3 (2.4)
Leiomyosarcoma 3 (4.4) 3 (2.4)
Lymphosarcoma 2 (2.9) 2 (1.6)
Undifferentiated sarcoma 2 (2.9) 2 (1.6)
Anaplastic spindle cell sarcoma 1 (1.5) 1 (0.8)
Liposarcoma 1 (1.5) 1 (0.8)
Stromal sarcoma 1 (1.5) 1 (0.8)
Total No. malignant liver lesions (%) 68 (100)a 68 (54.4)a
Benign liver lesions
Nodular hyperplasia 26 (37.7) 26 (20.8)
Hydrophic vacuolar hepatopathy 16 (23.2) 16 (12.8)
Hepatoma 6 (8.7) 6 (4.8)
Hepatitis 4 (5.8) 4 (3.2)
Cholangiohepatitis 2 (2.9) 2 (1.6)
Fibrosis 2 (2.9) 2 (1.6)
Lymphoplasmacytic hepatitis 2 (2.9) 2 (1.6)
a Some dogs had multiple lesions on histopathology, thus absolute numbers 
and percentages do not add up to 125 and 100% respectively
Table 1 (continued)
Liver biopsies obtained in the study No. (% 
of total)
No. (% of 125 
dogs)
Necrosis 2 (2.9) 2 (1.6)
Cirrhosis 2 (2.9) 2 (1.6)
Extramedullary hematopoiesis 1 (1.4) 1 (0.8)
Hematoma 1 (1.4) 1 (0.8)
Lipogranuloma 1 (1.4) 1 (0.8)
Lymphohistiocytic hepatitis 1 (1.4) 1 (0.8)
Congestion 1 (1.4) 1 (0.8)
Infarct 1 (1.4) 1 (0.8)
Cholestasis 1 (1.4) 1 (0.8)
Total No. benign liver lesions (%) 69 (100)a 69 (55.2)a
Table 2 Number of dogs per type of splenic mass(es) (SM) 
and hepatic mass(es) (HM)
a One dog had two malignant splenic lesions
Malignant HM Benign HM Sum 
total 
of dogs
Malignant SM 60 23 83a
Benign SM 8 34 42
Sum total of dogs 68 57 125
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SM and HM undergoing splenectomy. Our study docu-
ments that 27% of dogs with SM and HM have benign 
pathology at both sites and therefore carry a good prog-
nosis. The present study also documents that 48% of dogs 
with SM and HM have malignant pathology at both sites. 
Of the 69 dogs in our study that were diagnosed with 
splenic HSA, 46 (66.7%) had HSA diagnosed in the liver; 
this is comparable to the results reported by Clendaniel 
et al. [11] where 29 of 58 (50%) of dogs with gross liver and 
splenic lesions had splenic HSA metastasis to the liver.
There are a multitude of studies documenting the sig-
nalment (age, sex, breed) of dogs with SM [3–5, 15, 18–
20]. Multiple studies have found no significant difference 
in the age of dogs diagnosed with benign versus malig-
nant SM [3, 5, 18, 19]. The present study demonstrates no 
significant difference in the age of dogs presenting with 
both SM and HM (10.1 years), versus those of the previ-
ously reported studies of SM alone.
Previous studies have found no consistent sex predilec-
tion for dogs with benign or malignant SM [5, 20]. The 
current study similarly did not find a sex predilection 
between dogs with benign or malignant lesions; however, 
the large majority of the study population was spayed and 
castrated. The authors speculate that the reason for the 
prevalence of gonadectomy was due to cultural and soci-
oeconomic reasons associated with the suburban New 
York geographical area of our study population.
Our study population was similar to previous reports 
of SM with respect to breed and weight. In the present 
study, the dog breeds found to have concurrent SM and 
HM were comparable to those in previous studies of SM, 
with mixed breed, Golden Retrievers, Labrador Retriev-
ers, and German Shepherd Dogs being overrepresented 
[4, 5, 15, 18, 19].
Further prospective studies are warranted and should 
be directed at quantification and characterization of SM 
and HM with different imaging modalities and gross 
examination. Clendaniel et al. [11] previously noted that 
multiple nodules, dark-colored nodules, and actively 
bleeding nodules were highly associated with malignancy 
of the liver. A study utilizing contrast harmonic ultra-
sonography of splenic masses and liver nodules showed 
that it was 100% sensitive and specific for differentiating 
a benign vs malignant processes of the liver; however, the 
same study found that benign and malignant processes 
of the spleen were indistinguishable utilizing the same 
modality [15]. Another study accurately differentiated 
benign from malignant focal hepatic and splenic lesions 
in dogs with magnetic resonance imaging; the overall 
sensitivity and specificity were 100 and 90%, respectively 
[21]. Cuccovillo et  al. [22] noted a positive predictive 
value of 74% for malignancy when one target lesion was 
visualized and an 81% positive predictive for malignancy 
if multiple target lesions were noted in the liver or the 
spleen on ultrasonography. Future studies should utilize 
the above mentioned modalities and visual characteris-
tics in series or parallel to better prognosticate cases with 
SM and HM.
Conclusions
Our data suggests that nearly 30% of dogs undergo-
ing surgery with both gross hepatic and splenic lesions 
have a favorable prognosis. While malignant neoplasia 
is most likely in cases with both SM and HM under-
going splenectomy, benign or treatable causes must 
be considered possible in each dog. This information 
should be provided to owners to facilitate making an 
informed decision of whether or not to pursue surgery 
after imaging.
Limitations
Limitations of the study were mainly due to the ret-
rospective nature. Only cases that underwent surgery 
were included in our study. At our hospital, preopera-
tive abdominal ultrasonography is routinely performed. 
34, 27%
31, 25% 56, 45%
4, 3%
60, 48%
Benign Spleen and Liver
Malignant Spleen or Liver
Malignant Spleen and Liver with 
Same Pathology
Malignant Spleen and Liver with 
Different Pathology
Fig. 1 Numbers and percentages of benign and malignant SM and HM (n = 125)
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Given that cases with suspected metastatic disease based 
on preoperative imaging were likely relayed to owners as 
such, a sampling bias is probable. The owners of those 
dogs may have elected euthanasia or palliative therapy at 
a higher rate than those of other dogs. Thus, our study 
population may be skewed towards a more favorable 
prognosis. However, at our hospital we do not recom-
mend euthanasia to owners just on the fact that lesions 
are noted on both organs and always mention that long-
term prognosis would be based on histopathology results.
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